Skip to content
Clinical Trials – home
Therapeutic area

Musculoskeletal and connective tissue disorders – page 61

  • 863 clinical trials
  • 359 recruiting
  • 328 conditions
  • 28 countries

Conditions in this area

328 conditions with trials, the busiest first

Clinical trials in Musculoskeletal and connective tissue disorders

863 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

863 clinical trials

Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Onfekafusp Alfa
  • Sponsor:Philogen S.p.A.

Cerebral palsy+1

Not recruiting
Registered drug
Countries:LatviaLatvia
  • Participants:0–17 years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Pharmaceuticals GmbH
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Tg Therapeutics Inc.
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Myasthenia gravis

Not recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Myasthenia gravis

Not recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gefurulimab
  • Sponsor:Alexion Pharmaceuticals Inc.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Garetosmab
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Doxorubicin
  • Sponsor:Asoc Grupo Espanol De Investigacion En Sarcomas
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Triamcinolone Hexacetonide
  • Sponsor:Oslo University Hospital HF

Lupus nephritis+1

Not recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vemircopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.